CN106806382A - Anti-cancer composition - Google Patents

Anti-cancer composition Download PDF

Info

Publication number
CN106806382A
CN106806382A CN201510867079.2A CN201510867079A CN106806382A CN 106806382 A CN106806382 A CN 106806382A CN 201510867079 A CN201510867079 A CN 201510867079A CN 106806382 A CN106806382 A CN 106806382A
Authority
CN
China
Prior art keywords
dha
dihydroxyacetone
platinum
cis
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201510867079.2A
Other languages
Chinese (zh)
Other versions
CN106806382B (en
Inventor
张建国
任武贤
王鹏
堐榜琴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanxi Yabao Investment Group Co ltd
Yabao Pharmaceutical Group Corp
Original Assignee
Shanxi Yabao Health Products Co Ltd
Shanxi Yabao Pharmaceutical Group Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201510867079.2A priority Critical patent/CN106806382B/en
Application filed by Shanxi Yabao Health Products Co Ltd, Shanxi Yabao Pharmaceutical Group Corp filed Critical Shanxi Yabao Health Products Co Ltd
Priority to US15/750,726 priority patent/US10300026B2/en
Priority to PCT/CN2016/083466 priority patent/WO2017032111A1/en
Priority to AU2016311704A priority patent/AU2016311704B2/en
Priority to EP16838371.9A priority patent/EP3342406B1/en
Priority to JP2018503509A priority patent/JP6533866B2/en
Priority to KR1020187004813A priority patent/KR101965319B1/en
Priority to CA2992629A priority patent/CA2992629C/en
Publication of CN106806382A publication Critical patent/CN106806382A/en
Application granted granted Critical
Publication of CN106806382B publication Critical patent/CN106806382B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides a kind of anti-tumor drug joint, it is made up of dihydroxyacetone (DHA) and cis-platinum.Tests prove that a combination of both can significantly improve the antitumous effect of cis-platinum, and its toxicity is not increased.Present invention also offers the purposes of the combination in antineoplastic is prepared of dihydroxyacetone (DHA) and dihydroxyacetone (DHA) and cis-platinum.

Description

Anti-cancer composition
Technical field
The present invention relates to the new application of known compound, anti-tumor drug is being prepared more particularly, to it In purposes.
Background technology
1,3-Dihydroxyacetone, English name 1,3-dihydroxyaeetone or dihydroxyacetone, letter DHA is written as, is simplest three carbon ketose, outward appearance is white or the crystallization of off-white powder shape, tool There is sweet, cool taste, easy moisture absorption is simultaneously decomposed.It is the knot of dimer (1,4-Dioxane) under general state Crystalline substance, can lentamente be dissolved in 1 part of water or in 15 parts of ethanol, be slightly soluble in ether, but through dissolving or adding It is hot then be changed into monomer, the organic solvent such as monomer is soluble in water, ethanol, acetone and ether, fusing point is It is 75~80 DEG C, water-soluble>250g·L-1(20 DEG C), when pH is 6.0, stabilization, is a kind of important change Work, bio feedstocks, medicine, pesticide synthesis intermediate and polyfunctional food additive, purposes are very wide It is general.
Dihydroxyacetone (DHA) plays the role of moisturizing, sun-proof and ultraviolet radiation preventing, can prevent moisture of skin Excessive vaporization, can serve as the formula material of cosmetics, have special-effect especially as suncream.Two Hydroxypropanone- is the intermediate product of glycometabolism, is played an important role during glycometabolism, with reduction The effect of pig body fat, improves lean meat percentage.Supplement dihydroxyacetone (DHA) can improve organism metabolism rate and fat Fat acid oxidase, can potentially active combustion fat and reduce body fat, thus with antiobesity action, and subtract The incidence of disease of few relevant disease, it is also possible to caused by improving insulin sensitivity and reducing high cholesterol meals Blood plasma cholesterol level, long-term supplement can make the blood sugar utilization rate increase and save Body development, to motion Member can then improve aerobic endurance achievement.
Dihydroxyacetone (DHA) (DHA) is although purposes, is used extensively alone or in combination currently without on it Report of the medicine in anti-tumor aspect effect.
Cis-platinum, the entitled cis diamino dichloro network platinum of chemistry belongs to cell cycle nonspecific agent (CCNSA), tool There is cytotoxicity, the DNA replication dna process of cancer cell can be suppressed, and damage structure on its cell membrane, There is stronger broad spectrum anticancer to act on.But its side effect is big, clinical manifestation is bone-marrow transplantation, leucocyte subtracts Less, strong gastrointestinal reaction, n and V diarrhoea etc., irreversible Toxicity of Kidney and kidney failure, Neurotoxicity, allergic reaction, electrolyte disturbance etc..Although cis-platinum has so strong toxicity, It is still at present the fiest-tire medication of clinical treatment solid tumor due to its definite wide spectrum tumor-inhibiting action.
But clinic can not possibly heighten the effect of a treatment by increasing cis-platinum consumption simply, therefore set up the connection of cis-platinum Close therapeutic regimen, tumor killing effect can be significantly increased in the case where its toxicity is not increased, be always swollen The important topic of knurl medical research.
The content of the invention
In order to solve above-mentioned at least one technical problem, join the invention provides dihydroxyacetone (DHA) and cis-platinum Share application of the medicine in anti-tumor aspect.
According to an aspect of the invention, there is provided a kind of antitumor medicine composition, its effectively into Dividing includes dihydroxyacetone (DHA) and cis-platinum.
According to another aspect of the present invention, there is provided a kind of anti-tumor drug joint, is by dihydroxy Acetone and cis-platinum are constituted.
One of according to the embodiment of the present invention, medication combined middle dihydroxyacetone (DHA) can be in oral formulations Form, cis-platinum can be in injection form.
In accordance with a further aspect of the present invention, there is provided purposes of the dihydroxyacetone (DHA) in medicine is prepared, institute Medicine is stated for antitumor, is that subject is administered simultaneously dihydroxyacetone (DHA) and cis-platinum.Administering mode can be with According to its each conventional method of administration, consumption and the frequency.
According to the present invention, purposes of the combination of dihydroxyacetone (DHA) and cis-platinum in medicine is prepared is additionally provided, The medicine is used for antitumor.
It is used for antineoplastic medicine box present invention also offers one kind, including dihydroxyacetone (DHA) and cis-platinum.
One of according to the embodiment of the present invention, dihydroxyacetone (DHA) and cis-platinum are arranged on difference in medicine box Container in.
Another implementation method of the invention, dihydroxyacetone (DHA) is in oral dosage form, and cis-platinum is in note Penetrate dosage form formula.
A kind of implementation method of the invention, the weight ratio of dihydroxyacetone (DHA) and cis-platinum is in medicine box 3375~4125:1.Preferably, the weight ratio of dihydroxyacetone (DHA) and cis-platinum is 3750:1.
It is described present invention also offers the purposes of the combination in medicine box is prepared of dihydroxyacetone (DHA) and cis-platinum Medicine box is used for antitumor.
The solution have the advantages that proved by experiment：
1 test material
1.1 test samples
Title：Dihydroxyacetone (DHA) (DHA) solid powder
Unit is provided：There is provided by Suzhou Ya Bao medicament research and developments Co., Ltd
Positive control：Cisplatin for injection (Cisplatin), lot number：2WA2A1408055A, production Producer:Qilu Pharmaceutical Co., Ltd., specification：20mg/ bottles
1.2 experimental animals
Kind, strain and grade：Balb/c-nude nude mouses, SPF grades
Source：Shanghai Ling Chang bio tech ltd
Credit number：SCXK (Shanghai) 2013-00185
Animal quality certification number:2013001812253
Body weight：16-18g (during arrival)
Sex：Male
2 testing programs
Nude mice by subcutaneous is inoculated with H460 cells (human large cell lung cancer cell line), treats that tumour is long to volume 100mm3During left and right, select that 36 gross tumor volumes are close, shape is preferably naked from 70 nude mices Mouse, is divided into 6 groups, every group of 6 animals；
DHA groups：P.o., administered volume is 0.1mL/10g, bid, totally three weeks；
DHA+Cisplatin groups：Dihydroxyacetone (DHA) (DHA)：P.o., administered volume is 0.1mL/10g, bid；Cisplatin:4mg/kg, volume injected 0.1mL/10g, i.p, is administered once for every 5 days, and totally three Week；
Cisplatin groups：4mg/kg, volume injected 0.1mL/10g, i.p, is administered once for every 5 days, Totally three weeks；
Blank group：0.9% sodium chloride injection, administering mode is with DHA groups.
3 experimental techniques
3.1 inoculations
3.1.1 recover and expand H460 cells；
3.1.2 it is to be amplified to enough cells, cell is collected, matched somebody with somebody with 1640 culture mediums without serum It is 2 × 10 into concentration7The cell suspension of cell/mL；
3.1.3 nude mice back right side subcutaneous vaccination, only, i.e., every nude inoculation cell number is 0.1mL/ 2×106；
3.1.4 70 nude mices are inoculated with altogether, and knurl situation and tumor size are observed after inoculation.
3.2 packet administrations
3.2.1 treat that tumour is long to volume 100mm3During left and right, 36 tumours are selected from 70 nude mices Volume is close, the preferable nude mice of shape, is divided into 6 groups, every group each 6.
3.2.2 it is grouped
With " 2 testing program "
3.3 medicines are prepared
DHA：Weigh solid powder 15.0g to be placed in 100mL volumetric flasks, use 5% glucose injection Liquid is settled to graduation mark, is rocked to being completely dissolved in ultrasound.4 DEG C of refrigeration when being not used.
DHA+Cisplatin:Solid powder dihydroxyacetone (DHA) 15.0g is weighed to be placed in 100mL volumetric flasks, Graduation mark is settled to 5% glucose injection, is rocked to being completely dissolved in ultrasound.Measure 0.6mg/mL cisplatin solutions 4.0mL adds 2.0mL physiological saline, is configured to 0.4mg/mL (4mg/kg) Cisplatin solution, 4 DEG C of refrigeration when being not used.
All samples configuration in every three days is once.
3.4 measurements
From administration the 1st day, 3 gross tumor volumes and body weight were measured weekly.Put to death nude mice within 22nd day, Take out tumour to weigh, take pictures, finally calculate tumour inhibiting rate.
3.5 evaluation indexes
Tumor volume change；The weight of animals changes；Last tumor weight.
4 Testing index and computational methods
4.1 gross tumor volumes (tumor volume, TV)
Computing formula is：TV=1/2 × a × b2, wherein a, b represent length and width respectively.
4.2 relative tumour volumes (relative tumor volume, RTV)
Computing formula is：RTV=TVt/TV1, wherein TV1(d during for sub-cage administration1) gross tumor volume, TVtGross tumor volume during to measure each time.
4.3 Relative tumor proliferation rates T/C (%)
Computing formula is：
TRTV：Treatment group RTV；CRTV：Blank control group RTV.
4.4 knurl weight tumour inhibiting rates IR (%)
Computing formula is：
TTW：Treatment group's knurl weight；CTW：Blank control group knurl weight；TW(tumor weight)：Tumour Weight.
5 result of the tests
Concrete outcome is shown in Table 1, table 2 and Fig. 1, Fig. 2 and Fig. 3.
Table 1：Number of animals, body weight, gross tumor volume (TV), relative tumour volume (RTV), Relative tumor proliferation rate (T/C)
***P<0.01v.s.Blank(RTV)*：0.01<P<0.05v.s.Blank(RTV)
Table 2：Knurl weight and knurl weight tumour inhibiting rate
*:0.01<P<0.05v.s.Blank
6 discussion of results
6.1 tumour growth situations：Result shows that each group gross tumor volume has preferable dispersion, mark , less than the 1/4 of mean, blank group tumour growth is good, the RTV=(1797.4 in test endpoint for quasi- deviation ±657.6)。
6.2 body weight：In whole process of the test, Cisplatin groups, DHA+Cisplatin, Body weight loss Substantially, remaining each group increases normal.
6.3 Cisplatin groups：Clearly, performance body weight is decreased obviously toxic reaction, temperature decline, Body weight loss about 16.7% in test endpoint, animal state is poor；Determine drug dosage schedule be every 5 days to Medicine once, final administration number of times 4 times.Cisplatin tumor killing effects substantially (P=0.04), it is last its T/C=60.3%, tumor-like hyperplasia is 44.6%.This also shows the test system reliability simultaneously, can use In evaluating drug effect.
6.4 DHA groups：Non-toxic reaction, does not show obvious tumor-inhibiting action in this test model.
6.5 DHA+Cisplatin groups：Toxic reaction, performance Body weight loss, temperature decline, Body weight loss about 15.7% during test endpoint, is numerically relatively used alone Cisplatin and has reduced.DHA Administration 2 times daily, it is to be administered once for every 5 days that Cisplatin determines drug dosage schedule, final administration number of times 4 It is secondary.This group of tumor killing effect clearly (P=0.0059), last its T/C=44.9%, tumor-like hyperplasia It is 53.3%.
6.6 brief summaries
In this experiment, DHA+Cisplatin groups are in human large cell lung cancer H460 cell transplantation knurls Tumor killing effect is significantly stronger than Cisplatin groups on model, and will not increase the toxicity of chemical drug cis-platinum, it is believed that DHA can play preferable tumor-inhibiting action with chemical drug Cisplatin.
The additional aspect of the present invention and advantage will be set forth in part in the description, partly will be from following Description in become obvious, or by it is of the invention practice recognize.
Brief description of the drawings
Of the invention above-mentioned and/or additional aspect and advantage to embodiment from retouching below in conjunction with the accompanying drawings Be will be apparent in stating and be readily appreciated that, wherein：
Fig. 1 each group relative tumour volume statisticses；
Fig. 2 each group experimental animal body weight statisticses；
Fig. 3 each group tumor weight statisticses；
The medicine box schematic diagram that Fig. 4 is provided for the present invention.
Specific embodiment
Embodiments of the invention are described below in detail, embodiment is exemplary, are only used for explaining this hair It is bright, and be not construed as limiting the claims.
Embodiment 1
Commercially available dihydroxyacetone (DHA) (DHA), crystallizes with pleasantly sweet white powder.DHA 300g, Hydroxypropyl methylcellulose 200g is added, conventional method is made 40, tablet, packs.Cis-platinum 0.0792g With sodium chloride 0.7g, distilled water 80ml is added, aseptic packaging is injection 4.By DHA tablets Inserted in same packing box with cis-platinum injections agent, conventional method is packaged as medicine box.
Embodiment 2
Commercially available dihydroxyacetone (DHA) (DHA) 312g, is equally divided into 40 parts, dries close under room temperature environment Package dresses up pouch.Cis-platinum 0.076g, is equally divided into 4 parts, and it is bottle to pack.Use the time-division Do not dissolved with glucose for injection.DHA is oral, 0.13g/kg (calculated by people's body weight 60kg, under Together), twice a day, it is continuous to use 20 days.Cisplatin instils or intramuscular injection, 0.317mg/kg, Every medication in 5 days is once.
Embodiment 3
Antineoplastic medicine box is as shown in Figure 4.
Built-in 4 bottles (102) of medicine box (101), pack cisplatin injections 5ml (dense respectively Degree 3.98mg/ml).40 sealing bags (103) separately are put, inside there is dihydroxyacetone (DHA) particle respectively 6.75g.Sterilizing syringe (104) and medicine cup (105) are also equipped with medicine box.When using, by two Hydroxypropanone- particle is placed in medicine cup (105), is dissolved in suitable quantity of water, after the meal orally, 112.5mg/kg, Twice a day.Cis-platinum syringe (104) intramuscular injection, 0.339mg/kg is injected 1 time for every 5 days.
Although an embodiment of the present invention has been shown and described, for one of ordinary skill in the art For, it is possible to understand that without departing from the principles and spirit of the present invention can be to these embodiments Various changes, modification, replacement and modification are carried out, the scope of the present invention is by appended claims and its waits Jljl limits.

Claims (10)

1. a kind of antitumor medicine composition, its active ingredient includes dihydroxyacetone (DHA) and cis-platinum.
2. a kind of anti-tumor drug joint, is made up of dihydroxyacetone (DHA) and cis-platinum.
3. as claimed in claim 2 medication combined, wherein dihydroxyacetone (DHA) is in oral dosage form, Cis-platinum is in injection form.
4. purposes of the dihydroxyacetone (DHA) in medicine is prepared, the medicine is used for antitumor, is tested Person is administered simultaneously dihydroxyacetone (DHA) and cis-platinum.
5. purposes of the combination of dihydroxyacetone (DHA) and cis-platinum in medicine is prepared, the medicine is used to resist Tumour.
6. it is a kind of to be used for antineoplastic medicine box, including dihydroxyacetone (DHA) and cis-platinum.
7. medicine box as claimed in claim 6, it is characterised in that dihydroxyacetone (DHA) and cis-platinum are set In different containers.
8. medicine box as claimed in claim 6, wherein dihydroxyacetone (DHA) are in oral dosage form, suitable Platinum is in injection form.
9. medicine box as claimed in claim 6, the weight ratio of wherein dihydroxyacetone (DHA) and cis-platinum is 3375~4125:1.
10. purposes of the combination of dihydroxyacetone (DHA) and cis-platinum in medicine box is prepared, the medicine box is used to resist Tumour.
CN201510867079.2A 2015-08-24 2015-12-01 Anticancer composition Active CN106806382B (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN201510867079.2A CN106806382B (en) 2015-12-01 2015-12-01 Anticancer composition
PCT/CN2016/083466 WO2017032111A1 (en) 2015-08-24 2016-05-26 Use of dihydroxyacetone in preparation of anti-tumour drug
AU2016311704A AU2016311704B2 (en) 2015-08-24 2016-05-26 Use of dihydroxyacetone in preparation of anti-cancer medicaments
EP16838371.9A EP3342406B1 (en) 2015-08-24 2016-05-26 Dihydroxyacetone for use in the preparation of an anti-tumour drug
US15/750,726 US10300026B2 (en) 2015-08-24 2016-05-26 Use of dihydroxyacetone in preparation of anti-cancer medicaments
JP2018503509A JP6533866B2 (en) 2015-08-24 2016-05-26 Use of dihydroxyacetone for producing antineoplastic agents
KR1020187004813A KR101965319B1 (en) 2015-08-24 2016-05-26 Use of dihydroxyacetone in the manufacture of antitumor drugs
CA2992629A CA2992629C (en) 2015-08-24 2016-05-26 Use of dihydroxyacetone in preparation of anti-cancer medicaments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510867079.2A CN106806382B (en) 2015-12-01 2015-12-01 Anticancer composition

Publications (2)

Publication Number Publication Date
CN106806382A true CN106806382A (en) 2017-06-09
CN106806382B CN106806382B (en) 2020-09-18

Family

ID=59108168

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510867079.2A Active CN106806382B (en) 2015-08-24 2015-12-01 Anticancer composition

Country Status (1)

Country Link
CN (1) CN106806382B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111467329A (en) * 2020-05-22 2020-07-31 张建国 Application of 1, 3-dihydroxyacetone and 2, 4-dihydroxybenzoic acid in preparing food and medicine for treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1141769A (en) * 1995-02-16 1997-02-05 默克专利股份有限公司 Usage of dihydroxy acetone
CN101234788A (en) * 2008-02-05 2008-08-06 昆明贵研药业有限公司 Method for synthesizing antineoplastic medicine cisplatin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1141769A (en) * 1995-02-16 1997-02-05 默克专利股份有限公司 Usage of dihydroxy acetone
CN101234788A (en) * 2008-02-05 2008-08-06 昆明贵研药业有限公司 Method for synthesizing antineoplastic medicine cisplatin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111467329A (en) * 2020-05-22 2020-07-31 张建国 Application of 1, 3-dihydroxyacetone and 2, 4-dihydroxybenzoic acid in preparing food and medicine for treating cancer

Also Published As

Publication number Publication date
CN106806382B (en) 2020-09-18

Similar Documents

Publication Publication Date Title
CN103221040A (en) Disulfiram formulation and uses thereof
CN114831931B (en) Medicinal solution with antitumor synergistic attenuation effect and medicinal composition containing medicinal solution
CN107028876B (en) Polyethylene glycol electrolyte oral liquid and preparation method thereof
CN111870609A (en) Intestinal flora regulator and application thereof
CN106806382A (en) Anti-cancer composition
CN105311004B (en) The application of curcumin and its pharmaceutical salts
CN107737136A (en) A kind of purposes of pharmaceutical composition in preventing and/or treating hyperlipidemia and be hypoglycemic
SA04250273B1 (en) Pharmaceutical composition containing histone deacetylase inhibitor
CN105054068A (en) Saccharomyces cerevisiae glutathione nutritional preparation
WO2017032111A1 (en) Use of dihydroxyacetone in preparation of anti-tumour drug
CN1981870A (en) Invert-sugar powdery injection and its production
CN104546697B (en) A kind of Dexibuprofen injection pharmaceutical composition and preparation method thereof
US10300026B2 (en) Use of dihydroxyacetone in preparation of anti-cancer medicaments
CN102727429B (en) Pidotimod injection with modified stability, and preparation method thereof
CN106806376A (en) The pharmaceutical composition of paracetamol and glycyrrhizic acid or its salt or derivatives thereof
CN115721614B (en) alpha-KG sustained release preparation and application thereof
CN103316017A (en) Bis(alpha-furancarboxylato)oxovanadium composition for treatment of diabetes
CN103877533B (en) Pharmaceutical composition of a kind for the treatment of diabetes containing metformin and preparation method thereof
CN107233307A (en) A kind of ibuprofen injection and preparation method thereof
CN102579419A (en) Novel anticancer application of chlorogenic acid
CN106619649A (en) Medicine composition for treating tuberculous pleurisy, method for preparing medicine composition and application thereof
CN105997983B (en) Application of the 5 hydroxymethyl furfural in preparing Anti-helicobacter pylori drugs
JP2016514143A (en) Methods and products for enhancing cellular uptake of drugs and nutritional supplements
CN107115342A (en) A kind of pharmaceutical composition for treating liver cancer
CN102429914A (en) Compound preparation having anti-tumor action

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1234991

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220608

Address after: 044600 No. 41, Yabao Road, Ruicheng County, Yuncheng City, Shanxi Province

Patentee after: Shanxi Yabao Investment Group Co.,Ltd.

Patentee after: Yabao Pharmaceutical Group Co., Ltd

Address before: 044699 No. 43, Yabao South Road, Ruicheng County, Yuncheng City, Shanxi Province

Patentee before: SHANXI YABAO HEALTH PRODUCTS Co.,Ltd.

Patentee before: Yabao Pharmaceutical Group Co., Ltd